1 year return (CAGR)
25.64%
Idorsia Ltd Exchange (SW, CHF)
IDIA.SW
4.41
+0.08 (+1.80%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
42.01%
5 year return (CAGR)
-25.21%
10 year return (CAGR)
-
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
1.19B
Price/Sales
5.40
Ent value
2.80B
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
79.75
EPS growth
-30.05%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 4.47 |
| Daily high | 4.49 |
| Daily low | 4.27 |
| Daily Volume | 853K |
| All-time high | 33.62 |
| 1y analyst estimate | 5.33 |
| Beta | 1.68 |
| EPS (TTM) | -1.07 |
| Dividend per share | 0.00 |
| Ex-div date | 16 Jun 2017 |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| IDIA.SW | S&P500 | |
| Current price drop from All-time high | -86.88% | -1.58% |
| Highest price drop | -98.12% | -56.47% |
| Date of highest drop | 20 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -53.05% | -10.64% |
| Avg time to new high | 62 days | 12 days |
| Max time to new high | 1708 days | 1805 days |
News
The FDA recognizes through this designation both the clinical evidence supporting daridorexant and the significant unmet medical need in pediatric insomnia, where no FDA-approved pharmacological treat...
November 4, 2026
Idorsia will host an investor webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO™/JERAYGO™ (aprocitentan). Date: Wednesday, November 4, 2026Time: 14:...
November 3, 2026
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 142 million in the first nine months of 2026, with growth accelerating quarter-on-quarter. Idorsia reaffirms its fu...
October 29, 2026
Ad hoc announcement pursuant to Art. 53 LR Dedicated launch capital and shared participation in future revenues create a focused and capital-efficient pathway to realize the potential of TRYVIO/JERAYG...
October 29, 2026
FAB-KLEAR investigates lucerastat as a potential disease-modifying therapy targeting the kidney manifestations of Fabry disease. Nxera will contribute to development and hold commercialization rights ...
October 28, 2026
Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information. Alls...
October 27, 2026
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
Ad hoc announcement pursuant to Art. 53 LR In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of i...
October 26, 2026
Idorsia (SWX:IDIA) continues to attract attention after recent share price moves, with the stock down 4.5% on the latest trading day and showing weaker performance over the past month and the past thr...
September 25, 2026
Idorsia has given investors a wild ride over the past few years, and the big question now is whether the current share price can be squared with the revenue the business is generating. With the stock ...
September 24, 2026
Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence”Lower schedule expected to enhance patient access i...
August 11, 2026